Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

3.99USD
15 Aug 2017
Change (% chg)

-- (--)
Prev Close
$3.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
127,736
52-wk High
$12.58
52-wk Low
$2.93

OMED.OQ

Chart for OMED.OQ

About

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include... (more)

Overall

Beta: 2.82
Market Cap(Mil.): $150.15
Shares Outstanding(Mil.): 37.63
Dividend: --
Yield (%): --

Financials

  OMED.OQ Industry Sector
P/E (TTM): -- 79.65 32.40
EPS (TTM): -2.38 -- --
ROI: -75.79 3.61 14.92
ROE: -- 5.40 16.17

BRIEF-Oncomed Pharmaceuticals Q2 loss per share $0.40

* Q2 revenue $6.2 million versus $6.7 million Source text for Eikon: Further company coverage:

Aug 02 2017

BRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

* Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

May 04 2017

BRIEF-BVF Partners reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17

* BVF Partners LP reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17 - SEC filing Source text for Eikon: Further company coverage:

Apr 27 2017

BRIEF-Oncomed reports workforce reduction

* Oncomed Pharmaceuticals Inc - oncomed will reduce its workforce by approximately 50 percent, resulting in 64 remaining full-time employees

Apr 24 2017

OncoMed's lung cancer drug fails mid-stage study, shares tumble

OncoMed Pharmaceuticals Inc's shares were jolted for a second time in a week after the company said on Monday its experimental lung cancer drug failed a mid-stage study.

Apr 17 2017

UPDATE 2-OncoMed's lung cancer drug fails mid-stage study, shares tumble

* To also discontinue enrollment in colorectal cancer drug trial

Apr 17 2017

BRIEF-Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

* Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

Apr 17 2017

OncoMed's lung cancer drug fails mid-stage study

April 17 OncoMed Pharmaceuticals Inc said on Monday its experimental drug failed a mid-stage study for the treatment of lung cancer.

Apr 17 2017

OncoMed sinks as cancer drug fails; Bayer opts against licensing drugs

(In this April 10th story, corrects paragraphs 1 and 11 to drop the words "stem cell")

Apr 11 2017

CORRECTED-UPDATE 2-OncoMed sinks as cancer drug fails; Bayer opts against licensing drugs

April 10 OncoMed Pharmaceuticals Inc said it would discontinue a trial testing its experimental therapy demcizumab as an initial treatment for advanced pancreatic cancer, after the addition of the drug to standard-of-care failed a mid-stage study.

Apr 11 2017

Competitors

  Price Chg
Amgen, Inc. (AMGN.OQ) $170.04 --
Astellas Pharma Inc (4503.T) ¥1,399 +14.50
AstraZeneca plc (AZN.L) 4,466.50 +10.00
Bayer AG (BAYGn.DE) €108.05 +1.00
Bayer AG (BAYE.F) -- --
Celgene Corporation (CELG.OQ) $131.37 --
Roche Holding Ltd. (ROG.S) CHF245.70 +0.70
Roche Holding Ltd. (RO.S) CHF247.60 +1.60
GlaxoSmithKline plc (GSK.L) 1,498.50 +4.00
Johnson & Johnson (JNJ.N) $133.38 -0.10

Earnings vs. Estimates